Table 1 Baseline characteristics of patients treated with systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
| Â | Original Data Set | Matched Data Set | ||||
|---|---|---|---|---|---|---|
Variables | salvage HT | systemic CT | P | salvage HT | systemic CT | P |
Sample size, No. | 99 | 199 | Â | 71 | 71 | Â |
Variables at initial treatment | ||||||
 Histology | ||||||
  SCC | 70 (70.3) | 142 (71.4) | 0.766 | 52 (73.2) | 52 (73.2) | 1 |
  ADC / ADSC | 29 (29.3) | 57 (28.1) |  | 19 (26.8) | 19 (26.8) |  |
 Stage | ||||||
  I | 26 (26.3) | 8 (4.0) | < 0.001 | 15 (21.1) | 11 (15.5) | 0.608 |
  II | 43 (43.4) | 57 (28.6) |  | 33 (46.5) | 37 (52.1) |  |
  III | 29 (29.3) | 107 (53.8) |  | 22 (31.0) | 23 (32.4) |  |
  IV | 1 (1.0) | 27 (13.6) |  | 1 (1.4) | 0 (0) |  |
 Tumor size, mm | 54 (20–110) | 57 (10–100) | 0.085 | 55 (27–110) | 50 (25–96) | 0.238 |
 Parametrial invasion | ||||||
  yes | 66 (67.3) | 178 (90.4) | < 0.001 | 51 (71.8) | 55 (77.5) | 0.44 |
  no | 32 (32.7) | 19 (9.6) |  | 20 (28.2) | 16 (22.5) |  |
 Pelvic lymph node metastasis | ||||||
  yes | 43 (44.8) | 119 (60.4) | 0.015 | 32 (45.1) | 40 (56.3) | 0.735 |
  no | 53 (55.2) | 78 (39.6) |  | 39 (54.9) | 31 (43.7) |  |
 Para-aortic lymph node metastasis | ||||||
  yes | 8 (8.2) | 21 (10.7) | 0.506 | 7 (9.9) | 13 (18.3) | 0.148 |
  no | 89 (91.8) | 175 (89.3) |  | 64 (90.1) | 58 (81.7) |  |
Variables regarding definitive RT | ||||||
 IBCT | ||||||
  yes | 88 (88.9) | 161 (80.9) | 0.08 | 61 (85.9) | 66 (93.0) | 0.172 |
  no | 11 (11.1) | 38 (19.1) |  | 10 (14.1) | 5 (7.0) |  |
 Concurrent chemotherapy | ||||||
  yes | 89 (89.9) | 166 (83.4) | 0.134 | 66 (93.0) | 65 (91.5) | 0.754 |
  no | 10 (10.1) | 33 (16.6) |  | 5 (7.0) | 6 (8.5) |  |
 Boost irradiation | ||||||
  yes | 20 (20.2) | 54 (27.3) | 0.184 | 19 (26.8) | 22 (31.0) | 0.579 |
  no | 79 (79.8) | 144 (72.7) |  | 52 (73.2) | 49 (69.0) |  |
a Variables at the diagnosis of persistent cervical cancer | ||||||
 Age, year | 52 (26–82) | 52 (26–81) | 0.589 | 52 (26–82) | 53 (26–78) | 0.662 |
 Performance status | ||||||
  0 | 79 (83.2) | 115 (62.8) | 0.002 | 64 (90.1) | 66 (93.0) | 0.311 |
  1 | 16 (16.8) | 53 (29.0) |  | 7 (7.0) | 5 (7.0) |  |
  2 | 0 | 10 (5.5) |  | 0 | 0 |  |
  3 | 0 | 5 (2.7) |  | 0 | 0 |  |
 Sites of persistent tumor | ||||||
  cervix alone | 72 (72.7) | 97 (49.2) | < 0.001 | 20 (28.2) | 23 (32.4) | 0.468 |
  b cervix and the others | c 27 (27.3) | 100 (50.8) |  | c 51 (71.8) | 48 (67.6) |  |
 Tumor size of persistent cervical disease, mm | 21 (0–8) | 30 (0–70) | 0.011 | 22 (0–80) | 30 (0–68) | 0.156 |
  0- ≤ 40 mm | 70 (82.4) | 106 (70.2) | 0.055 | 58 (81.7) | 57 (80.3) | 1 |
   > 40 mm | 15 (17.6) | 45 (29.8) |  | 13 (18.3) | 14 (19.7) |  |
 Parametrial invasion of persistent tumor | ||||||
  yes, and no extension to the pelvic wall | 24 (25.8) | 68 (42.0) | < 0.001 | 17 (23.9) | 0 (0) | 0.749 |
  yes, and extension to the pelvic wall | 1 (1.1) | 33 (20.4) |  | 1 (1.4) | 22 (31.0) |  |
  no parametrial invasion | 68 (73.1) | 61 (37.7) |  | 53 (74.6) | 49 (69.0) |  |
 Vaginal invasion of persistent tumor | ||||||
  yes | 19 (20.0) | 44 (26.7) | 0.227 | 14 (19.7) | 24 (33.8) | 0.058 |
  no | 76 (80.0) | 121 (73.3) |  | 57 (80.3) | 47 (66.2) |  |
 Residual pelvic lymph node metastasis | ||||||
  0 | 82 (82.8) | 141 (72.3) | 0.027 | 58 (81.7) | 58 (81.7) | 0.29 |
  1 | 11 (11.1) | 20 (10.3) |  | 8 (11.3) | 4 (5.6) |  |
  2 or more | 6 (6.1) | 34 (17.4) |  | 5 (7.0) | 9 (12.7) |  |